mRNA Therapeutic Vaccines in the Fight Against Cancer
January 26, 2026
About 50 clinical studies are currently underway for the development of mRNA therapeutic vaccines against cancer, showing encouraging results. The mRNA technology is at the forefront, leveraging the experience gained during the COVID-19 pandemic. The combined vaccine from Moderna and Merck has shown nearly a 50% reduction in the risk of melanoma recurrence. These results have been monitored for five years and indicate that the benefits are long-lasting. Personalized mRNA-based therapies represent a promising advancement in oncology.